![2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4- carboxamide structure, CAS 912444-00-9](/structures/80000/60309_1_912444_00_9.png)
CAS Number912444-00-9
SynonymsABT-888 (Veliparib); 2-[(2R)-1-(tert-butoxycarbonyl)hexahydro-2-pyridinyl]acetic acid; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; Veliparib (ABT-888); Veliparib; (R)-1-Boc-2-piperidineacetic acid; 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide; 2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-4-carboxamide; (R)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl) acetic acid; (R)-N-Boc-2-piperidine acetic acid; 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4- carboxamide
Molecular FormulaC13H16N4O
Molecular Weight244.29
Purity≥98 (HPLC)%
Density1.3±0.1 g/cm3
Boiling Point579.0±40.0 °C at 760 mmHg
Appearancepowder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 912444-00-9 |
| Catalog No. | 2A-9060309 |
| Chinese Name | 维利帕尼 |
| Synonyms | ABT-888 (Veliparib); 2-[(2R)-1-(tert-butoxycarbonyl)hexahydro-2-pyridinyl]acetic acid; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; Veliparib (ABT-888); Veliparib; (R)-1-Boc-2-piperidineacetic acid; 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide; 2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-4-carboxamide; (R)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl) acetic acid; (R)-N-Boc-2-piperidine acetic acid; 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4- carboxamide |
| Molecular Formula | C13H16N4O |
| Molecular Weight | 244.29 |
| Purity | ≥98 (HPLC) |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 579.0±40.0 °C at 760 mmHg |
| Appearance | powder |
| Storage Condition | 2-8°C |
| Application | Veliparib is a potent PARP inhibitor with Ki of 5.2 and 2.9 nM for PARP1 and PARP2, respectively. |
| HTC | 2934999090 |
| MDL Number | MFCD16661059 |
| SMILES | CC1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1 |
| InChI Key | JNAHVYVRKWKWKQ-CYBMUJFWSA-N |
| NACRES Code | NA.21 |
| MSDS | msds/60309_1_912444_00_9.pdf |
| Use of | Veliparib is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively. Properties Name veliparib Synonym More Synonyms Veliparib (ABT-888) Biological Activity Description Veliparib is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Cell Cycle/DNA Damage >> PARP Signaling Pathways >> Epigenetics >> PARP Research Areas >> Cancer PARP-2:2.9 nM (Ki) PARP-1:5.2 nM (Ki) In Vitro Veliparib (ABT-888) is also tested against SIRT2, an enzyme that also uses NAD+ for catalysis, and found to be inactive (>5,000 nM). The receptor profile of Veliparib is determined in a panel of 74 receptor-binding assays at a concentration of 10 μM. Veliparib displaces control-specific binding at 50% or greater at the human H1(61%), the human 5-HT1A (91%), and the human 5-HT7 (84%) sites only. The IC50s for these three receptors are 5.3, 1.5, and 1.2 μM, respectively[1]. c-Met knockdown cells show 4.2- (shMet-A; 95% CI=4-4.5) or 4.6-fold (shMet-B; 95% CI=4.4-4.8) growth inhibition when treated with 60 μM Veliparib (ABT-888). When treated with 38 μM Veliparib, c-Met knockdown cells show 2- (shMet-A; 95% CI=1.5-2.5) or 1.9-fold (shMet-B; 95% CI=1.3-2.5) growth inhibition[2]. In HaCaT cells, at 6 h post-treatment by Veliparib (ABT-888), cell viability is significantly increases under 1,000 µM sulfur mustard (SM) exposure, whereas Veliparib does not protect cell viability under 100 µM SM exposure. Moreover, the addition of Veliparib no longer shows the protective effect at 24 h post SM exposure[3]. References [1]. Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. [2]. Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201. [3]. Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. Chemical & Physical Properties Molecular Formula C13H16N4O Exact Mass 244.132416 PSA 2.47340 Index of Refraction 1.653 InChIKey JNAHVYVRKWKWKQ-CYBMUJFWSA-N Safety Information HS Code 2934999090 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Heterocyclic Building Blocks | ||
|---|---|---|
| 2-Amino-3-(trifluoromethyl)pyridine | 183610-70-0 | 2A-9060255 |
| 5,7-Dichloro-1H-pyrazolo[4,3-d]pyriMidine | 1196157-42-2 | 2A-9060261 |
| 6-Methyl-2-(4-methylphenyl)imidazol[1,2-a]-pyridine-3-acetic acid | 189005-44-5 | 2A-9060274 |
| 3-IODO-OXETANE | 26272-85-5 | 2A-9060288 |
| 2-chloro-5-nitropyrimidine | 400822-47-1 | 2A-9060305 |
| 4-METHYL-1,2,3-THIADIAZOLE | 18212-62-9 | 2A-9060329 |
| ethyl 1,2,3-thiadiazole-5-carboxylate | 4100-14-5 | 2A-9060330 |
| 5-Methyl-1,2,3-thiadiazole | 50406-54-7 | 2A-9060331 |
| 5-CHLORO-4-METHYL-1,2,3-THIADIAZOLE | 53645-99-1 | 2A-9060332 |
| 3-Methylisothiazole-4-carboxylic acid | 15903-66-9 | 2A-9060333 |
| Browse all Heterocyclic Building Blocks products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS